Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORR

Loading news article.

Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORR | WAPE

Article summary

Related companies

Comments —